Related Experiment Video
Updated: May 31, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
Cholesterol elevation impairs glucose-stimulated Ca(2+) signaling in mouse pancreatic β-cells
Andy K Lee1, Valerie Yeung-Yam-Wah, Frederick W Tse
1Centre for Neuroscience, University of Alberta, Edmonton, Alberta, Canada T6G 2H7.
Abstract:
Recent studies have demonstrated that cholesterol elevation in pancreatic islets is associated with a reduction in glucose-stimulated insulin secretion, but the underlying cellular mechanisms remain elusive. Here, we show that cholesterol enrichment dramatically reduced the proportion of mouse β-cells that exhibited a Ca(2+) signal when stimulated by high glucose. When cholesterol-enriched β-cells were challenged with tolbutamide, there was a decrease in the amplitude of the Ca(2+) signal, and it was associated with a reduction in the cell current density of voltage-gated Ca(2+) channels (VGCC). Although the cell current densities of the ATP-dependent K(+) channels and the delayed rectifier K(+) channels were also reduced in the cholesterol-enriched β-cells, glucose evoked only a small depolarization in these cells. In cholesterol-enriched cells, the glucose-mediated increase in cellular ATP content was dramatically reduced, and this was related to a decrease in glucose uptake via glucose transporter 2 and an impairment of mitochondrial metabolism. Thus, cholesterol enrichment impaired glucose-stimulated Ca(2+) signaling in β-cells via two mechanisms: a decrease in the current density of VGCC and a reduction in glucose-stimulated mitochondrial ATP production, which in turn led to a smaller glucose-evoked depolarization. The decrease in VGCC-mediated extracellular Ca(2+) influx in cholesterol-enriched β-cells was associated with a reduction in the amount of exocytosis. Our findings suggest that defect in glucose-stimulated Ca(2+) signaling is an important mechanism underlying the impairment of glucose-stimulated insulin secretion in islets with elevated cholesterol level.
Insights
High cholesterol in pancreatic islet cells impairs glucose-stimulated insulin secretion by reducing calcium signaling. This is due to decreased calcium channel activity and impaired mitochondrial ATP production.
Area of Science:
- Cellular biology
- Endocrinology
- Metabolism
Background:
- Elevated cholesterol in pancreatic islets is linked to reduced insulin secretion.
- The cellular mechanisms behind this impairment are not fully understood.
Purpose of the Study:
- To investigate how cholesterol enrichment affects glucose-stimulated calcium signaling in pancreatic beta cells.
- To elucidate the cellular mechanisms underlying impaired insulin secretion due to high cholesterol.
Main Methods:
- Cholesterol enrichment of mouse beta cells.
- Measurement of calcium (Ca2+) signaling in response to glucose and tolbutamide.
- Assessment of voltage-gated calcium channel (VGCC) current density.
- Analysis of ATP production, glucose uptake, and mitochondrial metabolism.
- Evaluation of exocytosis.
Main Results:
- Cholesterol enrichment reduced glucose-stimulated Ca2+ signaling in beta cells.
- This was associated with decreased VGCC current density and impaired mitochondrial ATP production.
- Reduced glucose uptake and mitochondrial dysfunction contributed to lower ATP levels.
- Impaired Ca2+ influx via VGCC led to reduced insulin exocytosis.
Conclusions:
- Cholesterol enrichment impairs glucose-stimulated Ca2+ signaling in beta cells through reduced VGCC activity and mitochondrial ATP production.
- These defects contribute to the reduction in glucose-stimulated insulin secretion observed in hypercholesterolemic conditions.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Type II Diabetes II: Pathophysiology
Insulin Secretory Vesicles
Chronic Pancreatitis II: Pathophysiology
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Acute Pancreatitis II: Pathophysiology

